AU2019385480B2 - Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders - Google Patents

Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders Download PDF

Info

Publication number
AU2019385480B2
AU2019385480B2 AU2019385480A AU2019385480A AU2019385480B2 AU 2019385480 B2 AU2019385480 B2 AU 2019385480B2 AU 2019385480 A AU2019385480 A AU 2019385480A AU 2019385480 A AU2019385480 A AU 2019385480A AU 2019385480 B2 AU2019385480 B2 AU 2019385480B2
Authority
AU
Australia
Prior art keywords
compound
disease
subject
following formula
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019385480A
Other languages
English (en)
Other versions
AU2019385480A1 (en
Inventor
Balaraman KALUVU
Charbel MOUSSA
Christian Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of AU2019385480A1 publication Critical patent/AU2019385480A1/en
Application granted granted Critical
Publication of AU2019385480B2 publication Critical patent/AU2019385480B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2019385480A 2018-11-20 2019-11-20 Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders Active AU2019385480B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769791P 2018-11-20 2018-11-20
US62/769,791 2018-11-20
PCT/US2019/062387 WO2020106825A1 (en) 2018-11-20 2019-11-20 Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders

Publications (2)

Publication Number Publication Date
AU2019385480A1 AU2019385480A1 (en) 2021-07-15
AU2019385480B2 true AU2019385480B2 (en) 2025-04-24

Family

ID=70774015

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019385480A Active AU2019385480B2 (en) 2018-11-20 2019-11-20 Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders

Country Status (10)

Country Link
US (2) US12246009B2 (enExample)
EP (1) EP3883935A4 (enExample)
JP (2) JP7629200B2 (enExample)
KR (1) KR102902341B1 (enExample)
CN (2) CN120040470A (enExample)
AU (1) AU2019385480B2 (enExample)
CA (1) CA3120639A1 (enExample)
IL (2) IL283271B1 (enExample)
MX (2) MX2021005875A (enExample)
WO (1) WO2020106825A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204868A1 (en) * 2021-01-14 2022-07-21 Charbel MOUSSA Usp13 inhibitors and methods of use thereof
CN113713082B (zh) * 2021-08-27 2023-07-18 福建医科大学 一种用于阿尔茨海默症的纳米自噬诱导剂及其制备方法与应用
CN116626294B (zh) * 2022-09-20 2024-07-09 菲创生物医学技术(广州)有限公司 盘状结构域受体2在诊断神经退行性疾病中的应用及相关的计算机可读介质
US20240423995A1 (en) * 2023-06-15 2024-12-26 Georgetown University C-kit inhibitors and uses for treating and preventing inflammatory conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150030588A1 (en) * 2011-11-11 2015-01-29 Intellikine, Llc Combination of kinase inhibitors and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK6652000A3 (en) * 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US6379666B1 (en) 1999-02-24 2002-04-30 Edward L. Tobinick TNF inhibitors for the treatment of neurological, retinal and muscular disorders
EP1469810A4 (en) 2002-01-04 2009-01-14 Univ Rockefeller COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING BETA-AMYLOID PEPTIDE-RELATED DISORDERS
PT1478380E (pt) 2002-02-27 2006-12-29 Ab Science Utilização de inibidores de tirosina-cinases para tratar doenças do snc
US7496357B2 (en) 2002-03-04 2009-02-24 At&T Intellectual Property I, L.P. Automated telephone assistant device and associated methods
WO2004000313A2 (fr) 2002-06-24 2003-12-31 Exonhit Therapeutics Sa Traitement de la sclerose laterale amyotrophique avec des composes modulateurs de l’activite de pgc-1
ATE323702T1 (de) * 2002-08-06 2006-05-15 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
US7595306B2 (en) 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
ES2415665T3 (es) 2004-06-21 2013-07-26 Proteome Sciences Plc Procedimientos de cribado usando c-abl, fyn y sky en combinación con la proteína tau
EP1802321A4 (en) 2004-09-03 2009-12-02 Dana Farber Cancer Inst Inc COMPOSITIONS AND METHOD FOR MODULATING PGC-1-ALPHA FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND ILLNESSES
WO2007056208A2 (en) * 2005-11-02 2007-05-18 Cytovia, Inc. N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US8003662B2 (en) 2006-01-30 2011-08-23 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
CA2651898A1 (en) * 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
WO2007122634A2 (en) 2006-04-24 2007-11-01 Jubilant Biosys Limited Pyrimidinediones as tyrosine kinase inhibitors
JP2010527614A (ja) 2007-05-21 2010-08-19 エラン・フアルマ・インターナシヨナル・リミテツド パーキン基質およびアッセイ
EP2014663A1 (de) * 2007-07-12 2009-01-14 Bayer Schering Pharma AG Thienopyrimidylamine als Modulatoren des EP2-Rezeptors
WO2009151683A2 (en) 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US8618063B2 (en) 2008-04-09 2013-12-31 The Board Of Trustees Of The University Of Illinois Method for treating a synucleinopathy
WO2010017541A2 (en) 2008-08-08 2010-02-11 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
JP5690823B2 (ja) 2009-07-08 2015-03-25 レオ ファーマ アクティーゼルスカブ Ｊａｋ受容体およびタンパク質チロシンキナーゼ阻害薬としての複素環化合物
BR112012009094A8 (pt) 2009-10-23 2017-10-10 Novartis Ag método de tratamento de transtornos proliferativos e outras condições patológicas mediadas por bcr-abl, c-kit, ddr1,ddr2 ou atividade pdgf-r quinase
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
CA2788835A1 (en) 2010-02-05 2011-08-11 The Administrators Of The Tulane Educational Fund The use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with inhibitors of calcineurin or inhibitors of the mammalian target of rapamycin (mtor) complexes
EP2578590B1 (en) 2010-05-26 2017-08-16 Korea Institute of Science and Technology Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same
WO2012042684A1 (ja) 2010-10-01 2012-04-05 パナソニック株式会社 脂質二重膜の表側から裏側にカリウムイオンを輸送する方法
EP2665709B1 (en) 2011-01-21 2016-12-07 Sun Pharma Advanced Research Company Limited Diarylacetylene hydrazide containing tyrosine kinase inhibitors
IN2014CN04558A (enExample) * 2011-11-23 2015-09-18 Cancer Rec Tech Ltd
DK2844256T3 (da) 2012-05-02 2023-03-27 Univ Georgetown Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer
EP2852388A4 (en) 2012-05-23 2016-01-13 Univ Johns Hopkins COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
JP6318156B2 (ja) * 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
HK1219421A1 (zh) * 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
US20160089371A1 (en) * 2013-03-15 2016-03-31 Intellikine, Llc Combination of Kinase Inhibitors and Uses Thereof
WO2015051152A1 (en) 2013-10-03 2015-04-09 Leuvas Therapeutics Modulation of leukocyte activity in treatment of neuroinflammatory degenerative disease
AU2016274956A1 (en) * 2015-06-11 2017-12-14 Usher Iii Initiative, Inc. Methods of treating or preventing a proteopathy
JP2018525429A (ja) * 2015-08-28 2018-09-06 アッヴィ・インコーポレイテッド Ｓ１ｐ調節剤としての縮合複素環化合物
LT3463351T (lt) 2016-06-02 2022-06-10 Sun Pharma Advanced Research Company Limited Parkinsono ligos gydymas
WO2018081777A1 (en) * 2016-10-31 2018-05-03 Georgetown University Compositions and methods for treating neurodegenerative disorders
WO2018148533A1 (en) * 2017-02-09 2018-08-16 Georgetown University Compositions and methods for treating lysosomal storage disorders
AU2018235446B2 (en) 2017-03-15 2022-04-07 Sun Pharma Advanced Research Company Limited Novel amorphous dispersion of 4-Methyl-3-quinolin-3-ylethynyl-benzoic acid N'-(2-chloro-6-methyl-benzoyl) hydrazide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150030588A1 (en) * 2011-11-11 2015-01-29 Intellikine, Llc Combination of kinase inhibitors and uses thereof

Also Published As

Publication number Publication date
MX2025000838A (es) 2025-03-07
US20210369687A1 (en) 2021-12-02
CN120040470A (zh) 2025-05-27
KR102902341B1 (ko) 2025-12-18
IL327518A (en) 2026-05-01
JP7805052B2 (ja) 2026-01-23
US12246009B2 (en) 2025-03-11
AU2019385480A1 (en) 2021-07-15
CN113272308B (zh) 2025-03-18
JP2022507812A (ja) 2022-01-18
US20250177361A1 (en) 2025-06-05
WO2020106825A1 (en) 2020-05-28
KR20210095649A (ko) 2021-08-02
CN113272308A (zh) 2021-08-17
JP2025061797A (ja) 2025-04-11
IL283271A (en) 2021-07-29
MX2021005875A (es) 2021-09-23
EP3883935A4 (en) 2022-08-10
IL283271B1 (en) 2026-05-01
CA3120639A1 (en) 2020-05-28
JP7629200B2 (ja) 2025-02-13
EP3883935A1 (en) 2021-09-29

Similar Documents

Publication Publication Date Title
AU749088C (en) Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of Alzheimer's disease and dementias
US10925881B2 (en) Treatment of conditions associated with hyperinsulinaemia
US20250177361A1 (en) Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders
WO2000067734A2 (de) Verwendung von phthalazine-derivaten
US12630555B2 (en) Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists
Bonda et al. Novel therapeutics for Alzheimer's disease: an update
US8378112B2 (en) Glycyrrhetinic acid derivative and use thereof
KR20220118484A (ko) Oga 억제제 화합물
Guerrini et al. Development of ligands at γ-aminobutyrric acid type A (GABAA) receptor subtype as new agents for pain relief
JP2011518188A (ja) リソソーム調節のための化合物および使用方法
JP2023523454A (ja) グルコシルセラミド合成酵素のピリジン阻害剤及びそれらを使用する治療方法
JP2005075834A (ja) 神経変性疾患の処置
US20140248634A1 (en) Vimentin as a biomarker for the progression of myeloproliferative neoplasms
US20210261527A1 (en) Oga inhibitor compounds
US11426406B2 (en) Compositions and methods for treating lysosomal storage disorders
US9388181B2 (en) Substituted 1,2,3,4-tetrahydropyrido[3,4-E] pyrrolo[1,2-A]pyrimidines as kinase
WO2026006830A1 (en) Compositions and methods of treating diseases and disorders characterized by blood-brain barrier deterioration or reactive oxygen species generation
CN113228201A (zh) 治疗青光眼的钙蛋白酶-2选择性抑制剂化合物
US20150217004A1 (en) Carbamate compounds and methods of use in diseases of the nervous system
RU2799454C2 (ru) Терапевтический препарат для лечения нейродегенеративных заболеваний и его применение
CN115348966A (zh) 靶向线粒体的异缩酮/isolevuglandin清除剂及其用途
EP4043442A1 (en) 6-methyluracil derivatives with anticholinesterase activity and their use
WO2019046534A1 (en) INDOLOQUINOLINE COMPOUNDS DEUTTERED
US20160096832A1 (en) Kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)